

# Gerard Dijkstra

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9585352/publications.pdf>

Version: 2024-02-01

239  
papers

13,986  
citations

36203

51  
h-index

25716

108  
g-index

244  
all docs

244  
docs citations

244  
times ranked

18496  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cigarette Smoke Increases Risk for Colorectal Neoplasia in Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 798-805.e1.	2.4	12
2	New Therapeutic Approach for Intestinal Fibrosis Through Inhibition of pH-Sensing Receptor GPR4. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 109-125.	0.9	10
3	Are all dietary fibers equal for patients with inflammatory bowel disease? A systematic review of randomized controlled trials. <i>Nutrition Reviews</i> , 2022, 80, 1179-1193.	2.6	14
4	The Effect of Phenotype and Genotype on the Plasma Proteome in Patients with Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 414-429.	0.6	13
5	Western and Carnivorous Dietary Patterns are Associated with Greater Likelihood of IBD Development in a Large Prospective Population-based Cohort. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 931-939.	0.6	37
6	P126 The predictive value of the modified Rutgeerts score at index endoscopy after primary ileocolic resection in patients with Crohn's disease for the risk of re-resection and severe endoscopic inflammation after long-term follow-up. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i214-i214.	0.6	0
7	P509 Biomarkers of neutrophil activity and extracellular matrix turnover predict long-term response to vedolizumab in patients with Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i468-i469.	0.6	1
8	DOP15 Fluorescent labelled vedolizumab for real-time visualization and quantification of local drug distribution and pharmacodynamics in Inflammatory Bowel Diseases during endoscopy. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i064-i065.	0.6	1
9	DOP75 Effectiveness and Safety of tofacitinib versus vedolizumab in Patients with Ulcerative Colitis; A Nationwide, ICC Registry study. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i118-i120.	0.6	0
10	P176 The effect of induction therapy with infliximab or vedolizumab on hepcidin and iron status in patients with Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i244-i245.	0.6	0
11	DOP63 Real World Effectiveness, Safety and Pharmacokinetics of Switching Intravenous Vedolizumab Maintenance treatment to Subcutaneous Vedolizumab Therapy for Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i108-i109.	0.6	1
12	P611 Serological biomarkers of type VI and XXII collagen formation predict and monitor infliximab treatment response in patients with Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i541-i541.	0.6	0
13	P606 Use of TNF- $\pm$ -antagonists and systemic steroids is associated with attenuated immunogenicity against SARS-CoV-2 in fully vaccinated patients with Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i538-i538.	0.6	1
14	P577 Mucosal eosinophil abundance in non-inflamed colonic tissue predict response to vedolizumab induction therapy in inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i517-i518.	0.6	1
15	P687 Prevalence of iron deficiency and anaemia in the outpatient Inflammatory Bowel Disease population: a Dutch national cross-sectional study. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i589-i589.	0.6	0
16	P284 Prophylactic medication for the prevention of endoscopic recurrence after ileocolonic resection in Crohn's disease: a prospective study based on clinical risk stratification. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i316-i317.	0.6	2
17	Indications, Postoperative Management, and Long-term Prognosis of Crohn's Disease After Ileocecal Resection: A Multicenter Study Comparing the East and West. <i>Inflammatory Bowel Diseases</i> , 2022, 28, S16-S24.	0.9	2
18	HIGH INADEQUATE SURVEILLANCE RATES IN COLITIS-ASSOCIATED ADVANCED NEOPLASIA: A MULTICENTER RETROSPECTIVE STUDY. <i>Gastrointestinal Endoscopy</i> , 2022, 95, AB110-AB111.	0.5	0

#	ARTICLE	IF	CITATIONS
19	Long-Term Dietary Patterns Are Reflected in the Plasma Inflammatory Proteome of Patients with Inflammatory Bowel Disease. <i>Nutrients</i> , 2022, 14, 2522.	1.7	4
20	The Effect of the COVID-19 Pandemic in Intestinal Rehabilitation and Transplant Patients: Initial Results of the Intestinal Rehabilitation and Transplant Association's International Survey. <i>Transplantation</i> , 2022, 106, 1289-1292.	0.5	0
21	Serological biomarkers of type I, III and IV collagen turnover are associated with the presence and future progression of stricturing and penetrating Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 675-693.	1.9	12
22	Mucosal Eosinophil Abundance in Non-Inflamed Colonic Tissue Is Associated with Response to Vedolizumab Induction Therapy in Inflammatory Bowel Disease. <i>Journal of Clinical Medicine</i> , 2022, 11, 4141.	1.0	1
23	Whole exome sequencing analyses reveal gene-microbiota interactions in the context of IBD. <i>Gut</i> , 2021, 70, gutjnl-2019-319706.	6.1	26
24	Genetic Risk Scores Identify Genetic Aetiology of Inflammatory Bowel Disease Phenotypes. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 930-937.	0.6	8
25	High-Dose Vitamin D Does Not Prevent Postoperative Recurrence of Crohn's Disease in a Randomized Placebo-Controlled Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1573-1582.e5.	2.4	20
26	Habitual dietary intake of IBD patients differs from population controls: a case-control study. <i>European Journal of Nutrition</i> , 2021, 60, 345-356.	1.8	22
27	Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life. <i>Gut</i> , 2021, 70, 1266-1274.	6.1	40
28	Endoscopic imaging in inflammatory bowel disease: current developments and emerging strategies. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 115-126.	1.4	11
29	Environmental factors associated with biological use and surgery in inflammatory bowel disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1022-1034.	1.4	2
30	Decreasing Trends in Intestinal Resection and Re-Resection in Crohn's Disease. <i>Annals of Surgery</i> , 2021, 273, 557-563.	2.1	21
31	SMART-IBD: Better Health Care from the Patient's Perspective. , 2021, , 87-93.		2
32	Treatment of severe acute ulcerative colitis in SARS-CoV-2 infected patients: report of three cases and discussion of treatment options. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110125.	1.4	7
33	Increased Risk of High-grade Cervical Neoplasia in Women with Inflammatory Bowel Disease: A Case-controlled Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1464-1473.	0.6	10
34	Inflammation status modulates the effect of host genetic variation on intestinal gene expression in inflammatory bowel disease. <i>Nature Communications</i> , 2021, 12, 1122.	5.8	16
35	Outcome of Reverse Switching From CT-P13 to Originator Infliximab in Patients With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1954-1962.	0.9	17
36	Trajectories of Fatigue in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1919-1930.	0.9	9

#	ARTICLE	IF	CITATIONS
37	Food and Food Groups in Inflammatory Bowel Disease (IBD): The Design of the Groningen Anti-Inflammatory Diet (GrAID). <i>Nutrients</i> , 2021, 13, 1067.	1.7	50
38	Ustekinumab for Crohn's Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, a Nationwide Prospective Observational Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1920-1930.	0.6	22
39	Long-term dietary patterns are associated with pro-inflammatory and anti-inflammatory features of the gut microbiome. <i>Gut</i> , 2021, 70, 1287-1298.	6.1	246
40	Biallelic variants in <i>LIG3</i> cause a novel mitochondrial neurogastrointestinal encephalomyopathy. <i>Brain</i> , 2021, 144, 1451-1466.	3.7	28
41	P394 Serological biomarkers of type III and IV collagen remodeling predict and monitor infliximab treatment response in patients with Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S403-S404.	0.6	0
42	P339 Pregnant women with perianal Crohn's Disease: suggestions for the improvement of the current guideline on delivery method. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S364-S364.	0.6	0
43	OP39 The effect of phenotype and genotype on the plasma proteome in patients with Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S036-S039.	0.6	1
44	Bioelectrical Impedance Analysis and Mid-Upper Arm Muscle Circumference Can Be Used to Detect Low Muscle Mass in Clinical Practice. <i>Nutrients</i> , 2021, 13, 2350.	1.7	12
45	Immune checkpoint inhibitor treatment induces colitis with heavy infiltration of CD8 <sup>+</sup> T cells and an infiltration pattern that resembles ulcerative colitis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 479, 1119-1129.	1.4	11
46	Infliximab formulation strategy for a stable ileo-colonic targeted oral dosage form intended for the topical treatment of inflammatory bowel disease. <i>Journal of Drug Delivery Science and Technology</i> , 2021, 64, 102552.	1.4	3
47	Vitamin C Supplementation in Healthy Individuals Leads to Shifts of Bacterial Populations in the Gut: A Pilot Study. <i>Antioxidants</i> , 2021, 10, 1278.	2.2	35
48	Polygenetic risk scores do not add predictive power to clinical models for response to anti-TNF $\pm$ therapy in inflammatory bowel disease. <i>PLoS ONE</i> , 2021, 16, e0256860.	1.1	3
49	Development and Characterisation of Antibody-Based Optical Imaging Probes for Inflammatory Bowel Disease. <i>Pharmaceuticals</i> , 2021, 14, 922.	1.7	4
50	Dietary Intake Pattern is Associated with Occurrence of Flares in IBD Patients. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1305-1315.	0.6	28
51	A combination of fecal calprotectin and human beta-defensin 2 facilitates diagnosis and monitoring of inflammatory bowel disease. <i>Gut Microbes</i> , 2021, 13, 1943288.	4.3	4
52	Isotype-specific Antibody Responses to <i>Mycobacterium avium paratuberculosis</i> Antigens Are Associated With the Use of Biologic Therapy in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1253-1263.	0.6	6
53	The Citrullinated and MMP-degraded Vimentin Biomarker (VICM) Predicts Early Response to Anti-TNF $\pm$ Treatment in Crohn's Disease. <i>Journal of Clinical Gastroenterology</i> , 2021, 55, 59-66.	1.1	10
54	Efficacy of anti-TNF dosing interval lengthening in adolescents and young adults with inflammatory bowel disease in sustained remission (FREE-study): protocol for a partially randomised patient preference trial. <i>BMJ Open</i> , 2021, 11, e054154.	0.8	5

#	ARTICLE	IF	CITATIONS
55	Change in liverfunction tests in patients switched from olive oil based tpn to fish oil containing tpn. Clinical Nutrition ESPEN, 2021, 46, S782.	0.5	0
56	Inulin-grown <i>Faecalibacterium prausnitzii</i> cross-feeds fructose to the human intestinal epithelium. Gut Microbes, 2021, 13, 1993582.	4.3	12
57	Long-term Evaluation of Allogeneic Bone Marrow-derived Mesenchymal Stromal Cell Therapy for Crohn's Disease Perianal Fistulas. Journal of Crohn's and Colitis, 2020, 14, 64-70.	0.6	80
58	Ustekinumab for Crohn's Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study. Journal of Crohn's and Colitis, 2020, 14, 33-45.	0.6	124
59	Vedolizumab for Inflammatory Bowel Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study. Clinical Pharmacology and Therapeutics, 2020, 107, 1189-1199.	2.3	24
60	Riboflavin Supplementation in Patients with Crohn's Disease [the RISE-UP study]. Journal of Crohn's and Colitis, 2020, 14, 595-607.	0.6	63
61	Senescent Stem and Transient Amplifying Cells in Crohn's Disease Intestine. Inflammatory Bowel Diseases, 2020, 26, e8-e9.	0.9	14
62	Vulvar and vaginal neoplasia in women with inflammatory bowel disease. Digestive and Liver Disease, 2020, 52, 149-155.	0.4	3
63	P184 Temporary defunctioning ileostomy in therapy refractory Crohn's colitis: A viable alternative to immediate colorectal resection?. Journal of Crohn's and Colitis, 2020, 14, S230-S231.	0.6	0
64	Abdominal Wall Transplantation: Indications and Outcomes. Current Transplantation Reports, 2020, 7, 279-290.	0.9	9
65	Serological Biomarkers of Tissue Turnover Identify Responders to Anti-TNF Therapy in Crohn's Disease: A Pilot Study. Clinical and Translational Gastroenterology, 2020, 11, e00217.	1.3	16
66	Intestinal stenosis in Crohn's disease shows a generalized upregulation of genes involved in collagen metabolism and recognition that could serve as novel anti-fibrotic drug targets. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482095257.	1.4	9
67	Comorbidity, not patient age, is associated with impaired safety outcomes in vedolizumab- and ustekinumab-treated patients with inflammatory bowel disease: a prospective multicentre cohort study. Alimentary Pharmacology and Therapeutics, 2020, 52, 1366-1376.	1.9	28
68	Levels of Anti-Citrullinated Protein Antibodies and Rheumatoid Factor, Including IgA Isotypes, and Articular Manifestations in Ulcerative Colitis and Crohn's Disease. International Journal of Environmental Research and Public Health, 2020, 17, 8054.	1.2	7
69	Predicted efficacy of a pharmacogenetic passport for inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2020, 51, 1105-1115.	1.9	17
70	Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). Journal of Pathology, 2020, 251, 228-248.	2.1	791
71	Identification of Environmental Risk Factors Associated With the Development of Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2020, 14, 1662-1671.	0.6	23
72	Review: Local Tumor Necrosis Factor- $\alpha$ Inhibition in Inflammatory Bowel Disease. Pharmaceutics, 2020, 12, 539.	2.0	50

#	ARTICLE	IF	CITATIONS
73	Latent cytomegalovirus infection does not influence long-term disease outcomes in inflammatory bowel disease, but is associated with later onset of disease. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 891-896.	0.6	2
74	Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: retrospective long-term follow-up of the LIR!C trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 900-907.	3.7	75
75	Oxidative Stress and Redox-Modulating Therapeutics in Inflammatory Bowel Disease. <i>Trends in Molecular Medicine</i> , 2020, 26, 1034-1046.	3.5	169
76	Safe and Successful Treatment of Acute Cellular Rejection of an Intestine and Abdominal Wall Transplant With Vedolizumab. <i>Transplantation Direct</i> , 2020, 6, e527.	0.8	14
77	A comparative analysis of tioguanine versus low-dose thiopurines combined with allopurinol in inflammatory bowel disease patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1076-1086.	1.9	18
78	Limited added value of laboratory monitoring in thiopurine maintenance monotherapy in inflammatory bowel disease patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1353-1364.	1.9	5
79	DOP20 Can lifestyle and psychosocial factors predict flares of IBD; an exploratory study using telemedicine. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S059-S060.	0.6	1
80	Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 880-888.	1.9	64
81	IGL as a preservation solution in intestinal transplantation: a multicenter experience. <i>Transplant International</i> , 2020, 33, 963-965.	0.8	3
82	Pirfenidone Inhibits Cell Proliferation and Collagen I Production of Primary Human Intestinal Fibroblasts. <i>Cells</i> , 2020, 9, 775.	1.8	31
83	Cost-effectiveness of Telemedicine-directed Specialized vs Standard Care for Patients With Inflammatory Bowel Diseases in a Randomized Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1744-1752.	2.4	49
84	Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 123-134.	1.9	92
85	Long noncoding RNA H19X is a key mediator of TGF- $\beta$ -driven fibrosis. <i>Journal of Clinical Investigation</i> , 2020, 130, 4888-4905.	3.9	52
86	Clinical Course of Nodular Regenerative Hyperplasia in Thiopurine Treated Inflammatory Bowel Disease Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 568-570.	2.4	15
87	Development and validation of a web-based questionnaire to identify environmental risk factors for inflammatory bowel disease: the Groningen IBD Environmental Questionnaire (GIEQ). <i>Journal of Gastroenterology</i> , 2019, 54, 238-248.	2.3	16
88	Real-life study of safety of thiopurine-allopurinol combination therapy in inflammatory bowel disease: myelotoxicity and hepatotoxicity rarely affect maintenance treatment. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 407-415.	1.9	20
89	A Combined Set of Four Serum Inflammatory Biomarkers Reliably Predicts Endoscopic Disease Activity in Inflammatory Bowel Disease. <i>Frontiers in Medicine</i> , 2019, 6, 251.	1.2	37
90	Crohn's Disease in Clinical Remission Is Marked by Systemic Oxidative Stress. <i>Frontiers in Physiology</i> , 2019, 10, 499.	1.3	36

#	ARTICLE	IF	CITATIONS
91	Serum Free Thiols Are Superior to Fecal Calprotectin in Reflecting Endoscopic Disease Activity in Inflammatory Bowel Disease. <i>Antioxidants</i> , 2019, 8, 351.	2.2	29
92	Towards the Oral Treatment of Ileo-Colonic Inflammatory Bowel Disease with Infliximab Tablets: Development and Validation of the Production Process. <i>Pharmaceutics</i> , 2019, 11, 428.	2.0	17
93	OPO1 In-depth characterisation of host genetics and gut microbiome unravels novel host-microbiome interactions in inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S001-S001.	0.6	0
94	SLC39A8 missense variant is associated with Crohn's disease but does not have a major impact on gut microbiome composition in healthy subjects. <i>PLoS ONE</i> , 2019, 14, e0211328.	1.1	10
95	P166 A combined set of four serum inflammatory biomarkers reliably predicts endoscopic disease activity in inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S172-S172.	0.6	0
96	The Oxysterol Synthesising Enzyme CH25H Contributes to the Development of Intestinal Fibrosis. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1186-1200.	0.6	24
97	Off-label prescriptions of drugs used for the treatment of Crohn's disease or ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1293-1300.	1.9	6
98	Short Chain Fatty Acids (SCFAs)-Mediated Gut Epithelial and Immune Regulation and Its Relevance for Inflammatory Bowel Diseases. <i>Frontiers in Immunology</i> , 2019, 10, 277.	2.2	1,956
99	P784 Prevalence of cervical dysplasia in women with inflammatory bowel disease: data from the Parelinoer Institute (PSI) and PALGA database (PAP-IBD study). <i>Journal of Crohn's and Colitis</i> , 2019, 13, S513-S513.	0.6	0
100	DOP24 Intestinal acidification sensed by pH-sensing receptor GPR4 contributes to fibrogenesis. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S039-S039.	0.6	0
101	Anti-inflammatory Gut Microbial Pathways Are Decreased During Crohn's Disease Exacerbations. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1439-1449.	0.6	39
102	Assessing intestinal permeability in Crohn's disease patients using orally administered 52Cr-EDTA. <i>PLoS ONE</i> , 2019, 14, e0211973.	1.1	15
103	Nutritional Assessment in Inflammatory Bowel Disease (IBD) Development of the Groningen IBD Nutritional Questionnaires (GINQ). <i>Nutrients</i> , 2019, 11, 2739.	1.7	9
104	P4.29: Vedolizumab for chronic allograft enteropathy? A case report. <i>Transplantation</i> , 2019, 103, S155-S155.	0.5	0
105	Lymphoproliferative Disease in the Rectum 4 Years After Local Mesenchymal Stromal Cell Therapy for Refractory Perianal Crohn's Disease Fistulas: A Case Report. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 807-811.	0.6	11
106	Development of novel zero-order release budesonide tablets for the treatment of ileo-colonic inflammatory bowel disease and comparison with formulations currently used in clinical practice. <i>International Journal of Pharmaceutics</i> , 2019, 554, 366-375.	2.6	25
107	Single-Cell RNA Sequencing of Blood and Ileal T Cells From Patients With Crohn's Disease Reveals Tissue-Specific Characteristics and Drug Targets. <i>Gastroenterology</i> , 2019, 156, 812-815.e22.	0.6	58
108	The 1000IBD project: multi-omics data of 1000 inflammatory bowel disease patients; data release 1. <i>BMC Gastroenterology</i> , 2019, 19, 5.	0.8	68



#	ARTICLE	IF	CITATIONS
109	Methotrexate and Thioguanine Rescue Therapy for Conventional Thiopurine Failing Ulcerative Colitis Patients: A Multi-center Database Study on Tolerability and Effectiveness. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1558-1565.	0.9	7
110	Sex-Related Differences in Patients With Inflammatory Bowel Disease: Results of 2 Prospective Cohort Studies. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1298-1306.	0.9	53
111	Genomic and Expression Analyses Identify a Disease-Modifying Variant for Fibrostenotic Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 582-588.	0.6	16
112	Interplay of host genetics and gut microbiota underlying the onset and clinical presentation of inflammatory bowel disease. <i>Gut</i> , 2018, 67, 108-119.	6.1	590
113	Quantitative comparison of the neutralizing capacity, immunogenicity and cross-reactivity of anti-TNF- $\alpha$ biologicals and an Infliximab-biosimilar. <i>PLoS ONE</i> , 2018, 13, e0208922.	1.1	4
114	Gut microbiota composition and functional changes in inflammatory bowel disease and irritable bowel syndrome. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	351
115	P815 How to measure environmental exposures (the exposome) in inflammatory bowel disease?. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S525-S526.	0.6	0
116	Intestinal Activation of pH-Sensing Receptor OGR1 [GPR68] Contributes to Fibrogenesis. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1348-1358.	0.6	29
117	P464 Switching from the originator infliximab to biosimilar CT-P13 did not change the quality of life and clinical efficacy for IBD patients in stable remission in daily clinical practice (interim analysis). <i>Journal of Crohn's and Colitis</i> , 2018, 12, S339-S340.	0.6	1
118	Increased fecal calprotectin levels in Crohn's disease correlate with elevated serum Th1- and Th17-associated cytokines. <i>PLoS ONE</i> , 2018, 13, e0193202.	1.1	34
119	Smoking is Associated with Higher Disease-related Costs and Lower Health-related Quality of Life in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2017, 11, jjw160.	0.6	17
120	Intestinal rehabilitation for children with intestinal failure is cost-effective: a simulation study. <i>American Journal of Clinical Nutrition</i> , 2017, 105, 417-425.	2.2	14
121	Mechanisms of Cell Polarity Controlled Epithelial Homeostasis and Immunity in the Intestine. <i>Cold Spring Harbor Perspectives in Biology</i> , 2017, 9, a027888.	2.3	33
122	Misbalance in type III collagen formation/degradation as a novel serological biomarker for penetrating (Montreal B3) Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 26-39.	1.9	49
123	Agreement Between Home-Based Measurement of Stool Calprotectin and ELISA Results for Monitoring Inflammatory Bowel Disease Activity. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1742-1749.e2.	2.4	65
124	High prevalence of cachexia in newly diagnosed head and neck cancer patients: An exploratory study. <i>Nutrition</i> , 2017, 35, 114-118.	1.1	59
125	The role of gut microbiota in health and disease: In vitro modeling of host-microbe interactions at the aerobic-anaerobic interphase of the human gut. <i>Anaerobe</i> , 2017, 44, 3-12.	1.0	130
126	Nodular regenerative hyperplasia rarely leads to liver transplantation: A 20-year cohort study in all Dutch liver transplant units. <i>United European Gastroenterology Journal</i> , 2017, 5, 658-667.	1.6	23



#	ARTICLE	IF	CITATIONS
127	Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: a randomised controlled, open-label, multicentre trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 785-792.	3.7	196
128	Clinical Predictors of Future Nonadherence in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1568-1576.	0.9	38
129	Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. <i>Lancet</i> , 2017, 390, 959-968.	6.3	253
130	Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1499-1509.	0.9	76
131	A Regular Diet with Supplements is Sufficient for Intestinal Transplant Recipients. <i>Transplantation</i> , 2017, 101, S147.	0.5	0
132	Cohort profile: design and first results of the Dutch IBD Biobank: a prospective, nationwide biobank of patients with inflammatory bowel disease. <i>BMJ Open</i> , 2017, 7, e016695.	0.8	33
133	MON-P071: Increase in BMI after Intestinal Transplantation (ITX) in Adults without Total Parenteral Nutrition (TPN). <i>Clinical Nutrition</i> , 2017, 36, S205-S206.	2.3	0
134	OPO086...Long noncoding RNA H19X as a new therapeutic target for fibrosis. , 2017, , .		0
135	The Impact of Ethnicity and Country of Birth on Inflammatory Bowel Disease Phenotype: a Prospective Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1463-1470.	0.6	7
136	P374 Home or hospital-based analysis of stool calprotectin: assessing two methods for monitoring inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2017, 11, S268-S268.	0.6	0
137	DOP051 Serological biomarkers of tissue turnover can early identify responders to infliximab in Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2017, 11, S57-S57.	0.6	0
138	Prevalence of- and risk factors for work disability in Dutch patients with inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2017, 23, 8182-8192.	1.4	18
139	Identification of Clinical and Genetic Parameters Associated with Hidradenitis Suppurativa in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 106-113.	0.9	39
140	A simple coculture system shows mutualism between anaerobic faecalibacteria and epithelial Caco-2 cells. <i>Scientific Reports</i> , 2016, 5, 17906.	1.6	57
141	HSPA6 is an ulcerative colitis susceptibility factor that is induced by cigarette smoke and protects intestinal epithelial cells by stabilizing anti-apoptotic Bcl-XL. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016, 1862, 788-796.	1.8	16
142	Preface. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2016, 30, 143-144.	1.0	0
143	Proton pump inhibitors affect the gut microbiome. <i>Gut</i> , 2016, 65, 740-748.	6.1	885
144	Presentation of a nationwide multicenter registry of intestinal failure and intestinal transplantation. <i>Clinical Nutrition</i> , 2016, 35, 225-229.	2.3	18

#	ARTICLE	IF	CITATIONS
145	Smoking is Associated With Extra-intestinal Manifestations in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 455-461.	0.6	46
146	Evolution of Costs of Inflammatory Bowel Disease over Two Years of Follow-Up. <i>PLoS ONE</i> , 2016, 11, e0142481.	1.1	89
147	Pooled Resequencing of 122 Ulcerative Colitis Genes in a Large Dutch Cohort Suggests Population-Specific Associations of Rare Variants in MUC2. <i>PLoS ONE</i> , 2016, 11, e0159609.	1.1	21
148	Letter: infliximab therapy for patients with inflammatory bowel disease – some unanswered questions. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 1134-1134.	1.9	0
149	Multimodal treatment of perianal fistulas in Crohn's disease: seton versus anti-TNF versus advancement plasty (PISA): study protocol for a randomized controlled trial. <i>Trials</i> , 2015, 16, 366.	0.7	40
150	Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practice. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 529-539.	1.9	56
151	Current understanding of alloimmunity of the intestinal graft. <i>Current Opinion in Organ Transplantation</i> , 2015, 20, 286-294.	0.8	16
152	Predicting Endoscopic Disease Activity in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1.	0.9	24
153	Gastrointestinal pH and Transit Time Profiling in Healthy Volunteers Using the IntelliCap System Confirms Ileo-Colonic Release of ColoPulse Tablets. <i>PLoS ONE</i> , 2015, 10, e0129076.	1.1	95
154	Ulcerative colitis patients with an inflammatory response upon mesalazine cannot be desensitized: a randomized study. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 399-405.	0.6	5
155	Cost-effectiveness of intestinal transplantation for adult patients with intestinal failure: a simulation study. <i>American Journal of Clinical Nutrition</i> , 2015, 101, 79-86.	2.2	36
156	Allogeneic Bone Marrow-Derived Mesenchymal Stromal Cells Promote Healing of Refractory Perianal Fistulas in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2015, 149, 918-927.e6.	0.6	261
157	Self-reported Disability in Patients with Inflammatory Bowel Disease Largely Determined by Disease Activity and Illness Perceptions. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 369-377.	0.9	45
158	Comparison of Costs and Quality of Life in Ulcerative Colitis Patients with an Ileal Pouch-Anal Anastomosis, Ileostomy and Anti-TNF Therapy. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 1016-1023.	0.6	30
159	Fragments of Citrullinated and MMP-degraded Vimentin and MMP-degraded Type III Collagen Are Novel Serological Biomarkers to Differentiate Crohn's Disease from Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 863-872.	0.6	69
160	The ATG16L1 T300A allele impairs clearance of pathosymbionts in the inflamed ileal mucosa of Crohn's disease patients. <i>Gut</i> , 2015, 64, 1546-1552.	6.1	77
161	Performance of the Montreal classification for inflammatory bowel diseases. <i>World Journal of Gastroenterology</i> , 2014, 20, 15374.	1.4	49
162	Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation. <i>Gut</i> , 2014, 63, 1424-1430.	6.1	21

#	ARTICLE	IF	CITATIONS
163	Complex host genetics influence the microbiome in inflammatory bowel disease. <i>Genome Medicine</i> , 2014, 6, 107.	3.6	322
164	Suppression of p21 <sup>Rac</sup> Signaling and Increased Innate Immunity Mediate Remission in Crohn's Disease. <i>Science Translational Medicine</i> , 2014, 6, 233ra53.	5.8	30
165	Effect of Aging on Healthcare Costs of Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 637-645.	0.9	15
166	Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNF $\pm$ therapy: results from the COIN study. <i>Gut</i> , 2014, 63, 72-79.	6.1	430
167	Histopathologic and molecular evaluation of the Organ Procurement and Transplantation Network selection criteria for intestinal graft donation. <i>Journal of Surgical Research</i> , 2014, 189, 143-151.	0.8	12
168	Risk factors of work disability in patients with inflammatory bowel disease – A Dutch nationwide web-based survey. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 590-597.	0.6	52
169	Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease. <i>Gut</i> , 2014, 63, 451-457.	6.1	128
170	Correlation of Genetic Risk and Messenger RNA Expression in a Th17/IL23 Pathway Analysis in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 777-782.	0.9	20
171	Screening prior to biological therapy in Crohn's disease: Adherence to guidelines and prevalence of infections. Results from a multicentre retrospective study. <i>Digestive and Liver Disease</i> , 2014, 46, 881-886.	0.4	22
172	ColoPulse tablets perform comparably in healthy volunteers and Crohn's patients and show no influence of food and time of food intake on bioavailability. <i>Journal of Controlled Release</i> , 2013, 172, 618-624.	4.8	23
173	Adalimumab and Infliximab Are Equally Effective for Crohn's Disease in Patients Not Previously Treated With Anti-Tumor Necrosis Factor Agents. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 826-831.	2.4	72
174	Letter: detection of infliximab levels and anti-infliximab antibodies – comparison of three different assays; authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 282-282.	1.9	6
175	Westernized high-fat diet accelerates weight loss in dextran sulfate sodium-induced colitis in mice, which is further aggravated by supplementation of heme. <i>Journal of Nutritional Biochemistry</i> , 2013, 24, 1159-1165.	1.9	40
176	Thiopurines Are Associated with a Reduction in Surgical Re-resections in Patients with Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 2801-2808.	0.9	11
177	Adenomas in Patients with Inflammatory Bowel Disease Are Associated with an Increased Risk of Advanced Neoplasia. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 342-349.	0.9	21
178	Crohn's Disease Patients Have More IgG-Binding Fecal Bacteria than Controls. <i>Vaccine Journal</i> , 2012, 19, 515-521.	3.2	46
179	Impact of Human Granulocyte and Monocyte Isolation Procedures on Functional Studies. <i>Vaccine Journal</i> , 2012, 19, 1065-1074.	3.2	353
180	Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 765-771.	1.9	182

#	ARTICLE	IF	CITATIONS
181	Prevention of postoperative recurrence of Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 637-646.	0.6	42
182	Bone cells from patients with quiescent Crohn's disease show a reduced growth potential and an impeded maturation. <i>Journal of Cellular Biochemistry</i> , 2012, 113, 2424-2431.	1.2	5
183	A Non-Invasive, Low-Cost Study Design to Determine the Release Profile of Colon Drug Delivery Systems: A Feasibility Study. <i>Pharmaceutical Research</i> , 2012, 29, 2070-2078.	1.7	8
184	Lithium induces intestinotrophic effects in the healthy colon, but does not ameliorate dextran sulfate sodium-induced colitis in mice. <i>E-SPEN Journal</i> , 2012, 7, e16-e22.	0.5	1
185	Farnesoid X Receptor (FXR) Activation and FXR Genetic Variation in Inflammatory Bowel Disease. <i>PLoS ONE</i> , 2011, 6, e23745.	1.1	99
186	Effects of active and passive smoking on Crohn's disease and ulcerative colitis in a cohort from a regional hospital. <i>European Journal of Gastroenterology and Hepatology</i> , 2011, 23, 255-261.	0.8	25
187	Small bowel preservation for intestinal transplantation: a review. <i>Transplant International</i> , 2011, 24, 107-131.	0.8	54
188	Dietary heme adversely affects experimental colitis in rats, despite heat-shock protein induction. <i>Nutrition</i> , 2011, 27, 590-597.	1.1	24
189	Risk of malignant lymphoma in patients with inflammatory bowel diseases: A Dutch nationwide study. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 1837-1845.	0.9	88
190	Haplotype-based analysis of ulcerative colitis risk loci identifies both IL2 and IL21 as susceptibility genes in Han Chinese. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 2472-2479.	0.9	21
191	Functional Characterization of Mutations in the Myosin Vb Gene Associated With Microvillus Inclusion Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2011, 52, 307-313.	0.9	62
192	Malignant transformation of perianal and enterocutaneous fistulas is rare: results of 17 years of follow-up from The Netherlands. <i>Scandinavian Journal of Gastroenterology</i> , 2011, 46, 319-325.	0.6	49
193	Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human) Tj ETQq1 1 0.784314 rgBT / O <i>Inflammatory Bowel Diseases</i> , 2010, 16, 1708-1716.	0.9	39
194	Genetic Analysis in A Dutch Study Sample Identifies More Ulcerative Colitis Susceptibility Loci and Shows Their Additive Role in Disease Risk. <i>American Journal of Gastroenterology</i> , 2010, 105, 395-402.	0.2	39
195	Active and passive smoking behaviour and cessation plans of patients with Crohn's disease and ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 125-131.	0.6	24
196	Cytomegalovirus Infection Increases the Risk for Inflammatory Bowel Disease. <i>American Journal of Pathology</i> , 2010, 176, 3098.	1.9	9
197	Molecular prediction of disease risk and severity in a large Dutch Crohn's disease cohort. <i>Gut</i> , 2009, 58, 388-395.	6.1	162
198	Evidence for Local Expansion of IgA Plasma Cell Precursors in Human Ileum. <i>Journal of Immunology</i> , 2009, 183, 4871-4878.	0.4	32

#	ARTICLE	IF	CITATIONS
199	Effects of active and passive smoking on disease course of Crohn's disease and ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 1199-1207.	0.9	140
200	More right-sided IBD-associated colorectal cancer in patients with primary sclerosing cholangitis. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 1331-1336.	0.9	99
201	Monocytes and their pathophysiological role in Crohn's disease. <i>Cellular and Molecular Life Sciences</i> , 2009, 66, 192-202.	2.4	31
202	Colonoscopic surveillance improves survival after colorectal cancer diagnosis in inflammatory bowel disease. <i>British Journal of Cancer</i> , 2009, 101, 1671-1675.	2.9	141
203	Role of alkaline phosphatase in colitis in man and rats. <i>Gut</i> , 2009, 58, 379-387.	6.1	136
204	Diffuse enteritis after colectomy for ulcerative colitis: two case reports and review of the literature. <i>European Journal of Gastroenterology and Hepatology</i> , 2009, 21, 710-715.	0.8	33
205	Microscopic colitis: an unfamiliar but treatable disease. <i>Netherlands Journal of Medicine</i> , 2009, 67, 41-5.	0.6	3
206	Runt-related transcription factor 3 is associated with ulcerative colitis and shows epistasis with solute carrier family 22, members 4 and 5. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 1615-1622.	0.9	29
207	High frequency of early colorectal cancer in inflammatory bowel disease. <i>Gut</i> , 2008, 57, 1246-1251.	6.1	173
208	Up-regulation and Cytoprotective Role of Epithelial Multidrug Resistance-associated Protein 1 in Inflammatory Bowel Disease. <i>Journal of Biological Chemistry</i> , 2008, 283, 35630-35637.	1.6	30
209	JC Virus Infection in Colorectal Neoplasia That Develops after Liver Transplantation. <i>Clinical Cancer Research</i> , 2008, 14, 6717-6721.	3.2	29
210	Associations with tight junction genes PARD3 and MAGI2 in Dutch patients point to a common barrier defect for coeliac disease and ulcerative colitis An unusual case of ascites. <i>Gut</i> , 2007, 57, 463-467.	6.1	142
211	Association of interleukin-1 receptor-associated kinase M (IRAK-M) and inflammatory bowel diseases. <i>Scandinavian Journal of Gastroenterology</i> , 2007, 42, 827-833.	0.6	19
212	Calprotectin. <i>Annals of Surgery</i> , 2007, 246, 311-315.	2.1	69
213	Randomized, placebo-controlled trial of low molecular weight heparin in active ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2007, 13, 753-758.	0.9	33
214	Effects of different immunosuppressive regimens on regulatory T-cells in noninflamed colon of liver transplant recipients. <i>Inflammatory Bowel Diseases</i> , 2007, 13, 703-709.	0.9	24
215	Decreased P-glycoprotein (P-gp/MDR1) expression in inflamed human intestinal epithelium is independent of PXR protein levels. <i>Inflammatory Bowel Diseases</i> , 2007, 13, 710-720.	0.9	119
216	Genetic susceptibility has a more important role in pediatric-onset Crohn's disease than in adult-onset Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2007, 13, 1083-1092.	0.9	97

#	ARTICLE	IF	CITATIONS
217	Early bacterial dependent induction of inducible nitric oxide synthase (iNOS) in epithelial cells upon transfer of CD45RB <sup>high</sup> CD4 <sup>+</sup> T cells in a model for experimental colitis. <i>Inflammatory Bowel Diseases</i> , 2007, 13, 1467-1474.	0.9	19
218	Monitoring extracellular glutamate in hippocampal slices with a microsensor. <i>Journal of Neuroscience Methods</i> , 2007, 160, 37-44.	1.3	35
219	Thrombin generation in mesalazine refractory ulcerative colitis and the influence of low molecular weight heparin. <i>Journal of Thrombosis and Thrombolysis</i> , 2007, 24, 175-182.	1.0	9
220	Absence of association between the multidrug resistance (MDR1) gene and inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , 2006, 41, 1174-1182.	0.6	38
221	Inflammatory bowel disease after liver transplantation: A role for cytomegalovirus infection. <i>Scandinavian Journal of Gastroenterology</i> , 2006, 41, 205-211.	0.6	32
222	Cytoprotective role of Multidrug Resistance associated Protein (MRP1) in severe intestinal inflammation: involvement of the leukotriene pathway. <i>European Journal of Gastroenterology and Hepatology</i> , 2006, 18, A62-A63.	0.8	0
223	Matrix metalloproteinases as profibrotic factors in terminal ileum in Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2006, 12, 863-869.	0.9	40
224	Mantle cell lymphoma involving the appendiceal orifice as an unusual cause of lower gastrointestinal bleeding. <i>International Journal of Colorectal Disease</i> , 2006, 22, 99-100.	1.0	2
225	Inflammatory Bowel Disease After Liver Transplantation: Risk Factors for Recurrence and De Novo Disease. <i>American Journal of Transplantation</i> , 2006, 6, 1422-1429.	2.6	155
226	In vivo monitoring of extracellular glutamate in the brain with a microsensor. <i>Brain Research</i> , 2006, 1118, 34-42.	1.1	83
227	Susceptibility Genes in Pediatric-onset IBD Compared with Healthy Controls and Adult-onset IBD. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2006, 43, S43.	0.9	0
228	Guidelines for treatment with infliximab for Crohn's disease. <i>Netherlands Journal of Medicine</i> , 2006, 64, 219-29.	0.6	36
229	Synthesis and evaluation of a fluorine-18 labeled antisense oligonucleotide as a potential PET tracer for iNOS mRNA expression. <i>Nuclear Medicine and Biology</i> , 2004, 31, 605-612.	0.3	20
230	Targeting nitric oxide in the gastrointestinal tract. <i>Current Opinion in Investigational Drugs</i> , 2004, 5, 529-36.	2.3	26
231	Inflammatory bowel disease after liver transplantation: the effect of different immunosuppressive regimens. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 18, 33-44.	1.9	91
232	Increased Expression of Inducible Nitric Oxide Synthase in Circulating Monocytes from Patients with Active Inflammatory Bowel Disease. <i>Scandinavian Journal of Gastroenterology</i> , 2002, 37, 546-554.	0.6	40
233	Titres of anti-neutrophil cytoplasmic antibodies in inflammatory bowel disease are not related to disease activity. <i>QJM - Monthly Journal of the Association of Physicians</i> , 1999, 92, 651-658.	0.2	20
234	Inducible nitric oxide synthase is expressed on peripheral monocytes of patients with active inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 1998, 10, A45.	0.8	0

#	ARTICLE	IF	CITATIONS
235	Treatment of ulcerative colitis with mesalazine, prednisolon and azathioprine in a pregnant patient complicated by a primary cytomegalovirus infection. <i>European Journal of Gastroenterology and Hepatology</i> , 1998, 10, A90.	0.8	0
236	PREDICTION OF RECURRENT CYTOMEGALOVIRUS DISEASE AFTER TREATMENT WITH GANCICLOVIR IN SOLID-ORGAN TRANSPLANT RECIPIENTS. <i>Transplantation</i> , 1993, 55, 847-850.	0.5	53
237	Switching from Reference Infliximab to Biosimilar CT-P13 did not Change Quality of Life in Stable Inflammatory Bowel Disease Patients. <i>Crohn's &amp; Colitis</i> 360, 0, , .	0.5	0
238	Patients With Inflammatory Bowel Disease Show IgG Immune Responses Towards Specific Intestinal Bacterial Genera. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	12
239	HIF1 $\pm$ -Dependent Induction of TFRC by a Combination of Intestinal Inflammation and Systemic Iron Deficiency in Inflammatory Bowel Disease. <i>Frontiers in Physiology</i> , 0, 13, .	1.3	8